A Phase 2 interventional study of MEDI4736 monotherapy and tremelimumab+MEDI4736 in Metastatic Pancreatic Ductal Adenocarcinoma, sponsored by AstraZeneca. Completed at 21 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-02.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A Phase II Open-Label, Multi-Center Study of MEDI4736 Evaluated as Single Agent or in Combination with Tremelimumab in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
This is a Phase II, open-label, multi-center study to determine the efficacy and safety of MEDI4736 evaluated as single agent or in combination with tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) whose disease has progressed on fluoropyrimidine containing or gemcitabine-containing first-line chemotherapy.This study will consist of Part A, lead-in, as well as a possible expansion Part B.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria: -
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MEDI4736 via IV infusion.
Drug: MEDI4736 monotherapy
MEDI4736+tremelimumab via IV infusion.
Drug: tremelimumab+MEDI4736
MEDI4736 via IV infusion.
Drug pages: Tremelimumab · Durvalumab
tremelimumab+MEDI4736 via IV infusion.
Objective Response Rate (ORR) in All Patients Using Investigator Assessments According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
ORR was defined as the percentage of patients with at least one visit response of confirmed complete response (CR) or partial response (PR). CR was defined as disappearance of all target lesions (TLs) since baseline. Any pathological lymph nodes selected as TLs must have had reduction in short axis to \<10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of TLs, taking as reference the baseline sum of diameters. A confirmed response meant that a response of CR/PR was recorded at 1 visit and confirmed by repeat imaging, preferably at the next regularly scheduled imaging visit and not less than 4 weeks after the visit when response was first observed with no evidence of progression between the initial and CR/PR confirmation visits. Results are reported as percentage of patients with a confirmed response and percentage of patients with confirmed or unconfirmed responses (i.e., including single visit responses).
Time frame: From date of first infusion until confirmed disease progression or death (up to approximately 18 months for the data analysis cut-off)
Progression-free Survival (PFS) Using Investigator Assessments According to RECIST 1.1
PFS was defined as the time from the date of randomisation until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient had withdrawn from randomised therapy or had received another anti-cancer therapy prior to progression. Results are reported as median time from randomisation to PFS, calculated using the Kaplan-Meier technique.
Time frame: From date of first infusion until confirmed disease progression or death (up to approximately 18 months for the data analysis cut-off)
PFS Rate at 3 Months and at 6 Months
PFS was defined as the time from the date of randomisation until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient had withdrawn from randomised therapy or had received another anti-cancer therapy prior to progression. PFS rates were calculated using Kaplan-Meier estimates of the cumulative probability of PFS. The PFS rate at 3 months and 6 months was equivalent to the percentage of patients with PFS after 3 months and 6 months, respectively.
Time frame: From date of first infusion until confirmed disease progression or death (up to 3 months and 6 months)
Overall Survival (OS)
OS was defined as the time from the date of randomisation until death due to any cause. Results are reported as median OS, calculated using the Kaplan-Meier technique.
Time frame: From date of first infusion until death (up to approximately 18 months for the data analysis cut-off)
Survival Status, Presented as OS Rate, at 6 Months and at 12 Months
OS was defined as the time from the date of randomisation until death due to any cause. OS rates were calculated using Kaplan-Meier estimates of the cumulative probability of survival at each indicated time period. The OS rate at 6 months and 12 months was equivalent to the percentage of patients with OS after 6 months and 12 months, respectively.
Time frame: From date of first infusion until death (up to 6 months and 12 months)
Best Objective Response (BoR) Using Investigator Assessments According to RECIST 1.1
BoR was calculated based on the overall visit responses from each RECIST assessment. It was the best response a patient had following date of first dosing but prior to starting any subsequent cancer therapy and prior to RECIST progression or last evaluable assessment in absence of RECIST progression. Categorisation of BoR was based on RECIST using the following response categories: CR and PR for status of 'Response'; Stable Disease (SD) ≥6 weeks, Progressive Disease (PD) and Not Evaluable (NE) for status of 'Non-response'. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD was defined as at least a 20% increase in the sum of diameters of TLs taking as reference the smallest sum on study. NE was only relevant if any of the TLs were not assessed or not evaluable or had a lesion intervention at this visit. Results are reported as number of patients with BoR for each of the indicated categories.
Time frame: From date of first infusion until confirmed disease progression or death (up to approximately 18 months for the data analysis cut-off)
Disease Control Rate (DCR) Using Investigator Assessments According to RECIST 1.1
DCR at 3 months was defined as the percentage of patients who have a BoR of CR or PR in the first 3 months or who have demonstrated SD for a minimum interval of 13 weeks following the start of treatment. DCR at 6 months was defined as the percentage of patients who have a BoR of CR or PR in the first 6 months or who have demonstrated SD for a minimum interval of 26 weeks following the start of treatment. DCR at 12 months was defined as the percentage of patients who have a BoR of CR or PR in the first 12 months or who have demonstrated SD for a minimum interval of 52 weeks following the start of treatment. Results are reported as the percentage of patients with disease control for each of the indicated categories.
Time frame: From date of first infusion until confirmed disease progression or death (up to 3 months, 6 months and 12 months)
Pharmacokinetics (PK) of Durvalumab (MEDI4736)
To evaluate PK, blood samples were collected pre- and post-dose and durvalumab (MEDI4736) concentrations in serum were determined. On Day 1 of Cycles 1, 4 and 7 (Weeks 0, 12 and 24), PK samples were collected pre-dose (within 60 minutes prior to treatment with any IP) and post-dose at the end of infusion (within 10 minutes of end of infusion of durvalumab and within 10 minutes of end of infusion of tremelimumab \[for patients receiving durvalumab plus tremelimumab\]). On Day 1 of Cycle 2 (Week 4), PK samples were collected pre-dose (within 60 minutes prior to treatment with any IP) only. The 3-month follow-up sample for durvalumab was relative to the respective last dose. Results are reported as mean pre- or post-dose durvalumab concentrations as indicated by the individual categories (1 cycle=4 weeks). Samples below lower limit of quantification were treated as missing in the analyses.
Time frame: Blood samples were collected pre-dose on Day 1 (Week 0), Week 4, Week 12 and Week 24, post-dose on Day 1, Week 12 and Week 24, and additionally at 3 months after the last dose (follow-up).
PK of Tremelimumab
To evaluate PK, blood samples were collected pre- and post-dose and tremelimumab concentrations in serum were determined. On Day 1 of Cycles 1 and 4 (Weeks 0 and 12), PK samples were collected pre-dose (within 60 minutes prior to treatment with any IP) and post-dose at the end of infusion (within 10 minutes of end of infusion of tremelimumab). On Day 1 of Cycle 2 (Week 4), PK samples were collected pre-dose (within 60 minutes prior to treatment with any IP) only. The 3-month follow-up sample for tremelimumab was relative to the respective last dose. Results are reported as mean pre- or post-dose tremelimumab concentrations as indicated by the individual categories (1 cycle=4 weeks). Samples below lower limit of quantification were treated as missing in the analyses.
Time frame: Blood samples were collected pre-dose on Day 1 (Week 0), Week 4 and Week 12, post-dose on Day 1 and Week 12, and additionally at 3 months after the last dose (follow-up).
Presence of Antidrug Antibodies (ADAs) for Durvalumab (MEDI4736)
ADA prevalence was the proportion of the ADA evaluable set who had an ADA positive result at any point in time, baseline or post-baseline. ADA incidence (treatment-emergent ADA) was the sum of both treatment-induced (post-baseline ADA positive only) and treatment-boosted ADA positive patients as a proportion of the evaluable patient population. Treatment-boosted ADA was defined as baseline positive ADA titre boosted to a 4-fold or higher level following IP administration. Persistently positive was defined as positive at ≥2 post-baseline assessments (with ≥16 weeks between first and last positive) or positive at last post-baseline assessment. Transiently positive was defined as at least 1 post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive. Results are reported as number of patients with detectable anti-durvalumab antibodies satisfying each of the indicated categories. Note: 'positive' is denoted by 'pos' in some category titles.
Time frame: Immunogenicity samples were collected on Day 1 (Week 0), Week 4, Week 12 and Week 24, and additionally at 3 months and 6 months after the last dose (follow-up).
Presence of ADAs for Tremelimumab
ADA prevalence was the proportion of the ADA evaluable set who had an ADA positive result at any point in time, baseline or post-baseline. ADA incidence (treatment-emergent ADA) was the sum of both treatment-induced (post-baseline ADA positive only) and treatment-boosted ADA positive patients as a proportion of the evaluable patient population. Treatment-boosted ADA was defined as baseline positive ADA titre boosted to a 4-fold or higher level following IP administration. Persistently positive was defined as positive at ≥2 post-baseline assessments (with ≥16 weeks between first and last positive) or positive at last post-baseline assessment. Transiently positive was defined as at least 1 post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive. Results are reported as number of patients with detectable anti- tremelimumab antibodies satisfying each of the indicated categories. Note: 'positive' is denoted by 'pos' in some category titles.
Time frame: Immunogenicity samples were collected on Day 1 (Week 0), Week 4 and Week 12, and additionally at 3 months and 6 months after the last dose (follow-up).
First patient enrolled: 16 Nov 2015; Part A data cut-off: 26 May 2017. The study contained a Part B which was not opened; only Part A was conducted. Study assessed efficacy of durvalumab (MEDI4736) + tremelimumab combination therapy compared to durvalumab (MEDI4736) monotherapy. Study performed at 21 sites in 6 countries.
| Milestone | Durvalumab (MEDI4736) Plus Tremelimumab | Durvalumab (MEDI4736) Monotherapy |
|---|---|---|
| Started | 32 | 33 |
| Patients who received ip | 32 | 32 |
| Completed | 0 | 0 |
| Not completed | 32 | 33 |
| Withdrew: Death; any cause, entire study duration | 28 | 31 |
| Withdrew: Withdrawal by subject | 2 | 1 |
| Withdrew: Closure of part a | 2 | 1 |
ORR was defined as the percentage of patients with at least one visit response of confirmed complete response (CR) or partial response (PR). CR was defined as disappearance of all target lesions (TLs) since baseline. Any pathological lymph nodes selected as TLs must have had reduction in short axis to \<10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of TLs, taking as reference the baseline sum of diameters. A confirmed response meant that a response of CR/PR was recorded at 1 visit and confirmed by repeat imaging, preferably at the next regularly scheduled imaging visit and not less than 4 weeks after the visit when response was first observed with no evidence of progression between the initial and CR/PR confirmation visits. Results are reported as percentage of patients with a confirmed response and percentage of patients with confirmed or unconfirmed responses (i.e., including single visit responses).
| Percentage of participants | Durvalumab (MEDI4736) Plus Tremelimumab | Durvalumab (MEDI4736) Monotherapy |
|---|---|---|
| Confirmed responses only | 3.1 (0.08 to 16.22) | 0 (0 to 10.58) |
| Confirmed and unconfirmed responses | 3.1 (0.08 to 16.22) | 6.1 (0.74 to 20.23) |
PFS was defined as the time from the date of randomisation until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient had withdrawn from randomised therapy or had received another anti-cancer therapy prior to progression. Results are reported as median time from randomisation to PFS, calculated using the Kaplan-Meier technique.
| Months | Durvalumab (MEDI4736) Plus Tremelimumab | Durvalumab (MEDI4736) Monotherapy |
|---|---|---|
| Progression-free Survival (PFS) Using Investigator Assessments According to RECIST 1.1 | 1.5 (1.2 to 1.5) | 1.5 (1.3 to 1.5) |
PFS was defined as the time from the date of randomisation until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient had withdrawn from randomised therapy or had received another anti-cancer therapy prior to progression. PFS rates were calculated using Kaplan-Meier estimates of the cumulative probability of PFS. The PFS rate at 3 months and 6 months was equivalent to the percentage of patients with PFS after 3 months and 6 months, respectively.
| Percentage of participants | Durvalumab (MEDI4736) Plus Tremelimumab | Durvalumab (MEDI4736) Monotherapy |
|---|---|---|
| PFS rate at 3 months | 9.4 (2.4 to 22.3) | 10.9 (3.0 to 24.7) |
| PFS rate at 6 months | 9.4 (2.4 to 22.3) | 3.6 (0.3 to 15.4) |
OS was defined as the time from the date of randomisation until death due to any cause. Results are reported as median OS, calculated using the Kaplan-Meier technique.
| Months | Durvalumab (MEDI4736) Plus Tremelimumab | Durvalumab (MEDI4736) Monotherapy |
|---|---|---|
| Overall Survival (OS) | 3.1 (2.2 to 6.1) | 3.6 (2.7 to 6.1) |
OS was defined as the time from the date of randomisation until death due to any cause. OS rates were calculated using Kaplan-Meier estimates of the cumulative probability of survival at each indicated time period. The OS rate at 6 months and 12 months was equivalent to the percentage of patients with OS after 6 months and 12 months, respectively.
| Percentage of participants | Durvalumab (MEDI4736) Plus Tremelimumab | Durvalumab (MEDI4736) Monotherapy |
|---|---|---|
| Survival rate at 6 months | 36.2 (20.0 to 52.7) | 34.9 (19.2 to 51.1) |
| Survival rate at 12 months | 8.8 (1.8 to 22.8) | 6.3 (1.1 to 18.4) |
BoR was calculated based on the overall visit responses from each RECIST assessment. It was the best response a patient had following date of first dosing but prior to starting any subsequent cancer therapy and prior to RECIST progression or last evaluable assessment in absence of RECIST progression. Categorisation of BoR was based on RECIST using the following response categories: CR and PR for status of 'Response'; Stable Disease (SD) ≥6 weeks, Progressive Disease (PD) and Not Evaluable (NE) for status of 'Non-response'. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD was defined as at least a 20% increase in the sum of diameters of TLs taking as reference the smallest sum on study. NE was only relevant if any of the TLs were not assessed or not evaluable or had a lesion intervention at this visit. Results are reported as number of patients with BoR for each of the indicated categories.
| Participants | Durvalumab (MEDI4736) Plus Tremelimumab | Durvalumab (MEDI4736) Monotherapy |
|---|---|---|
| Response: Total | 1 | 0 |
| Response: CR | 0 | 0 |
| Response: PR | 1 | 0 |
| Non-response: Total | 31 | 33 |
| Non-response: Stable disease ≥6 weeks | 5 | 7 |
| Non-response: Progression of disease | 26 | 25 |
| Non-response: Not evaluable | 0 | 1 |
DCR at 3 months was defined as the percentage of patients who have a BoR of CR or PR in the first 3 months or who have demonstrated SD for a minimum interval of 13 weeks following the start of treatment. DCR at 6 months was defined as the percentage of patients who have a BoR of CR or PR in the first 6 months or who have demonstrated SD for a minimum interval of 26 weeks following the start of treatment. DCR at 12 months was defined as the percentage of patients who have a BoR of CR or PR in the first 12 months or who have demonstrated SD for a minimum interval of 52 weeks following the start of treatment. Results are reported as the percentage of patients with disease control for each of the indicated categories.
| Percentage of participants | Durvalumab (MEDI4736) Plus Tremelimumab | Durvalumab (MEDI4736) Monotherapy |
|---|---|---|
| At 3 months | 9.4 (1.98 to 25.02) | 6.1 (0.74 to 20.23) |
| At 6 months | 6.3 (0.77 to 20.81) | 0 (0.00 to 10.58) |
| At 12 months | 3.1 (0.08 to 16.22) | 0 (0.00 to 10.58) |
To evaluate PK, blood samples were collected pre- and post-dose and durvalumab (MEDI4736) concentrations in serum were determined. On Day 1 of Cycles 1, 4 and 7 (Weeks 0, 12 and 24), PK samples were collected pre-dose (within 60 minutes prior to treatment with any IP) and post-dose at the end of infusion (within 10 minutes of end of infusion of durvalumab and within 10 minutes of end of infusion of tremelimumab \[for patients receiving durvalumab plus tremelimumab\]). On Day 1 of Cycle 2 (Week 4), PK samples were collected pre-dose (within 60 minutes prior to treatment with any IP) only. The 3-month follow-up sample for durvalumab was relative to the respective last dose. Results are reported as mean pre- or post-dose durvalumab concentrations as indicated by the individual categories (1 cycle=4 weeks). Samples below lower limit of quantification were treated as missing in the analyses.
| Micrograms per millilitre (mcg/mL) | Durvalumab (MEDI4736) Plus Tremelimumab | Durvalumab (MEDI4736) Monotherapy |
|---|---|---|
| Cycle 1, Day 1, pre-infusion (Day 1) | 217.338 ± 345.4913 | — |
| Cycle 1, Day 1, post-infusion (Day 1) | 566.078 ± 151.4199 | 562.218 ± 152.3811 |
| Cycle 2, Day 1, pre-infusion (Day 29) | 100.417 ± 39.7229 | 98.668 ± 36.5072 |
| Cycle 4, Day 1, pre-infusion (Day 85) | 236.205 ± 98.8964 | 228.450 ± 36.8395 |
| Cycle 4, Day 1, post-infusion (Day 85) | 825.818 ± 322.8247 | 760.456 ± 100.6974 |
| Cycle 7, Day 1, pre-infusion (Day 169) | 166.736 ± 47.3872 | 152.706 ± NA |
| Cycle 7, Day 1, post-infusion (Day169) | 918.270 ± 98.4286 | 825.578 ± NA |
| 3-month follow-up | 38.456 ± NA | 19.684 ± 20.2664 |
To evaluate PK, blood samples were collected pre- and post-dose and tremelimumab concentrations in serum were determined. On Day 1 of Cycles 1 and 4 (Weeks 0 and 12), PK samples were collected pre-dose (within 60 minutes prior to treatment with any IP) and post-dose at the end of infusion (within 10 minutes of end of infusion of tremelimumab). On Day 1 of Cycle 2 (Week 4), PK samples were collected pre-dose (within 60 minutes prior to treatment with any IP) only. The 3-month follow-up sample for tremelimumab was relative to the respective last dose. Results are reported as mean pre- or post-dose tremelimumab concentrations as indicated by the individual categories (1 cycle=4 weeks). Samples below lower limit of quantification were treated as missing in the analyses.
| mcg/mL | Durvalumab (MEDI4736) Plus Tremelimumab |
|---|---|
| Cycle 1, Day 1, pre-infusion (Day 1) | 13.114 ± 11.7182 |
| Cycle 1, Day 1, post-infusion (Day 1) | 24.477 ± 6.3516 |
| Cycle 2, Day 1, pre-infusion (Day 29) | 4.880 ± 2.2623 |
| Cycle 4, Day 1, pre-infusion (Day 85) | 8.753 ± 4.9962 |
| Cycle 4, Day 1, post-infusion (Day 85) | 21.150 ± 5.8997 |
ADA prevalence was the proportion of the ADA evaluable set who had an ADA positive result at any point in time, baseline or post-baseline. ADA incidence (treatment-emergent ADA) was the sum of both treatment-induced (post-baseline ADA positive only) and treatment-boosted ADA positive patients as a proportion of the evaluable patient population. Treatment-boosted ADA was defined as baseline positive ADA titre boosted to a 4-fold or higher level following IP administration. Persistently positive was defined as positive at ≥2 post-baseline assessments (with ≥16 weeks between first and last positive) or positive at last post-baseline assessment. Transiently positive was defined as at least 1 post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive. Results are reported as number of patients with detectable anti-durvalumab antibodies satisfying each of the indicated categories. Note: 'positive' is denoted by 'pos' in some category titles.
| Participants | Durvalumab (MEDI4736) Plus Tremelimumab | Durvalumab (MEDI4736) Monotherapy |
|---|---|---|
| ADA prevalence | 1 | 5 |
| ADA incidence | 0 | 3 |
| ADA pos post-baseline and pos at baseline | 0 | 0 |
| ADA pos post-baseline and not detected at baseline | 0 | 3 |
| ADA not detected post-baseline and pos at baseline | 1 | 2 |
| Treatment-boosted ADA | 0 | 0 |
| Persistent positive | 0 | 3 |
| Transient positive | 0 | 0 |
| Never positive | 24 | 19 |
ADA prevalence was the proportion of the ADA evaluable set who had an ADA positive result at any point in time, baseline or post-baseline. ADA incidence (treatment-emergent ADA) was the sum of both treatment-induced (post-baseline ADA positive only) and treatment-boosted ADA positive patients as a proportion of the evaluable patient population. Treatment-boosted ADA was defined as baseline positive ADA titre boosted to a 4-fold or higher level following IP administration. Persistently positive was defined as positive at ≥2 post-baseline assessments (with ≥16 weeks between first and last positive) or positive at last post-baseline assessment. Transiently positive was defined as at least 1 post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive. Results are reported as number of patients with detectable anti- tremelimumab antibodies satisfying each of the indicated categories. Note: 'positive' is denoted by 'pos' in some category titles.
| Participants | Durvalumab (MEDI4736) Plus Tremelimumab |
|---|---|
| ADA prevalence | 2 |
| ADA incidence | 0 |
| ADA pos post-baseline and pos at baseline | 1 |
| ADA pos post-baseline and not detected at baseline | 0 |
| ADA not detected post-baseline and pos at baseline | 1 |
| Treatment-boosted ADA | 0 |
| Persistent positive | 0 |
| Transient positive | 1 |
| Never positive | 23 |
Collected over Treatment-emergent adverse event (TEAE) data is reported for the treatment period (up to 12 months) + follow-up (up to 90 days). Overall timeframe: up to approximately 15 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Durvalumab (MEDI4736) Plus Tremelimumab | 19/32 (59.4%) | 11/32 (34.4%) | 26/32 (81.3%) |
| Durvalumab (MEDI4736) Monotherapy | 16/32 (50%) | 9/32 (28.1%) | 26/32 (81.3%) |
| Event | Durvalumab (MEDI4736) Plus Tremelimumab | Durvalumab (MEDI4736) Monotherapy |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 3/32 | 0/32 |
| AscitesGastrointestinal disorders | 2/32 | 1/32 |
| PyrexiaGeneral disorders | 0/32 | 2/32 |
| CholangitisHepatobiliary disorders | 2/32 | 0/32 |
| Acute kidney injuryRenal and urinary disorders | 0/32 | 2/32 |
| Abdominal distensionGastrointestinal disorders | 1/32 | 0/32 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/32 | 1/32 |
| HaematemesisGastrointestinal disorders | 1/32 | 0/32 |
| HaematocheziaGastrointestinal disorders | 0/32 | 1/32 |
| Intestinal obstructionGastrointestinal disorders | 1/32 | 0/32 |
| Event | Durvalumab (MEDI4736) Plus Tremelimumab | Durvalumab (MEDI4736) Monotherapy |
|---|---|---|
| FatigueGeneral disorders | 6/32 | 9/32 |
| Decreased appetiteMetabolism and nutrition disorders | 8/32 | 8/32 |
| ConstipationGastrointestinal disorders | 5/32 | 7/32 |
| DyspepsiaGastrointestinal disorders | 6/32 | 2/32 |
| PyrexiaGeneral disorders | 6/32 | 2/32 |
| DiarrhoeaGastrointestinal disorders | 4/32 | 5/32 |
| NauseaGastrointestinal disorders | 4/32 | 5/32 |
| VomitingGastrointestinal disorders | 5/32 | 5/32 |
| HypothyroidismEndocrine disorders | 4/32 | 0/32 |
| AstheniaGeneral disorders | 3/32 | 4/32 |
All patients in the FAS who were randomised to treatment were included in the baseline analysis.
| Age, Continuous(Years) | Durvalumab (MEDI4736) Plus Tremelimumab | Durvalumab (MEDI4736) Monotherapy | Total |
|---|---|---|---|
| Mean | 61.3 ± 9.60 | 61.6 ± 9.54 | 61.5 ± 9.49 |
| Sex: Female, Male(Participants) | Durvalumab (MEDI4736) Plus Tremelimumab | Durvalumab (MEDI4736) Monotherapy | Total |
|---|---|---|---|
| Female | 17 | 14 | 31 |
| Male | 15 | 19 | 34 |
| Ethnicity (NIH/OMB)(Participants) | Durvalumab (MEDI4736) Plus Tremelimumab | Durvalumab (MEDI4736) Monotherapy | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 2 |
| Not Hispanic or Latino | 30 | 33 | 63 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Durvalumab (MEDI4736) Plus Tremelimumab | Durvalumab (MEDI4736) Monotherapy | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 15 | 10 | 25 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 17 | 22 | 39 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2015 to primary completion in Jun 2017, 18 months.
Results were first posted in Aug 2018, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Durvalumab · Tremelimumab
Anophthalmia with pulmonary hypoplasia